Cyclic Lipopeptides via Solid-Phase Synthesis for Antibacterial Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics are limited in their effectiveness against different pathogenic organisms and often lead to hypersensitivity and toxic effects, with existing methods struggling to generate daptomycin analogues with improved antibacterial activities due to production constraints.
Innovation Solution
Development of cyclic lipopeptides through chemical synthesis, allowing for modifications at specific positions and the introduction of unnatural amino acids, such as alkylated or acylated kynurenine, N-methyl indol-3-ylmethyl, sarcosine, and 2,3-diaminobutyric acid, to enhance antibacterial properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If daptomycin analogues are produced through fermentation and genetic engineering of non-ribosomal peptide synthetase, then production is feasible, but structural variations are limited and cannot achieve modifications at specific positions (Trp1, Thr4, Gly5, Orn6, Kyn13)
Solution Approach 1:
The patent employs solid-phase peptide synthesis (SPPS) to enable precise parameter changes at specific amino acid positions (Trp1, Thr4, Gly5, Orn6, Kyn13) of daptomycin analogues. This chemical synthesis approach allows systematic modification of individual residues while maintaining overall structural integrity, overcoming the structural limitations of fermentation-based methods.
Solution Approach 2:
The patent uses Fmoc-protected amino acids and standard peptide coupling reagents (such as HATU, DIC, EDC) as intermediaries to facilitate the stepwise assembly and modification of daptomycin analogues. These chemical intermediaries enable precise introduction of unnatural amino acids and modifications at specific positions that cannot be achieved through genetic engineering alone.
2Ease of manufacture
If daptomycin analogues are produced through chemoenzymatic and semisynthesis approaches, then some structural modifications are possible, but unnatural amino acids cannot be substituted and antibacterial activities do not improve beyond parent daptomycin
Solution Approach 1:
The patent systematically varies multiple parameters including amino acid sequence modifications at positions Trp1, Thr4, Gly5, Orn6, and Kyn13, as well as substituting natural amino acids with unnatural variants (such as N-methylated amino acids, D-amino acids, and non-proteinogenic amino acids). This comprehensive parameter exploration has yielded analogues with enhanced antibacterial activities against resistant strains compared to parent daptomycin.
Solution Approach 2:
The patent applies local quality modifications by introducing specific unnatural amino acids at strategic positions within the daptomycin structure. For example, N-methylated amino acids are introduced to enhance membrane permeability and resistance to proteolytic degradation, while D-amino acids are incorporated to improve metabolic stability. These localized modifications at specific positions (such as Trp1, Kyn13) produce targeted improvements in antibacterial activity without compromising overall structural function.
3Ease of operation
If traditional antibiotics are used, then treatment is simple, but hypersensitivity and toxic effects occur frequently
Solution Approach 1:
The patent modifies specific local regions of the daptomycin structure by introducing unnatural amino acids at positions known to influence toxicity and immunogenicity (such as Trp1, Kyn13, and the lipid tail region). These localized changes reduce hypersensitivity reactions and toxic effects while preserving the membrane-targeting mechanism of action, thereby maintaining treatment simplicity while reducing adverse effects.
Data Source
AI summary
Cyclic lipopeptides having one or more modifications relative to daptomycin, and methods of making them are provided. The cyclic lipopeptides can be used as antibacterial agents. The daptomycin analogues are generated by chemical synthesis, which makes introduction of an unnatural amino acid and any modification into daptomycin possible. Pharmaceutical compositions and method of use thereof for the disclosed daptomycin analogues are also provided.